Loading
In people with the inherited condition NF2 whose nerve and brain-lining tumours were growing despite earlier treatment, the kinase inhibitor brigatinib shrank some tumours, slowed the growth of all types and improved hearing in a third of affected ears without serious toxicity.
First sub-study of the adaptive platform trial INTUITT-NF2: 40 patients (median age 26) with NF2-related schwannomatosis and progressive target tumours (10 vestibular schwannomas, 8 non-vestibular schwannomas, 20 meningiomas, 2 ependymomas) received brigatinib.
After a median follow-up of 10.4 months, 10 percent of target tumours and 23 percent of all tumours had a radiographic response, with meningiomas and non-vestibular schwannomas benefiting most; annualised growth rates fell for all tumour types; hearing improved in 35 percent of eligible ears; pain scores fell; and there were no grade 4 or 5 treatment-related adverse events.
Brigatinib is the first drug shown to act across the tumour types of NF2-related schwannomatosis and is now offered for progressive tumours; the platform design lets further drugs be tested against the same benchmark.
Shares Vestibular schwannoma (acoustic neuroma), New England Journal of Medicine.
Shares Vestibular schwannoma (acoustic neuroma), New England Journal of Medicine.
Shares Vestibular schwannoma (acoustic neuroma), Meningioma.
Shares Vestibular schwannoma (acoustic neuroma), Meningioma.
Shares Vestibular schwannoma (acoustic neuroma), Meningioma.
Shares Vestibular schwannoma (acoustic neuroma), Meningioma.